Free Trial
NASDAQ:GUTS

Fractyl Health Q4 2023 Earnings Report

Fractyl Health logo
$1.27 0.00 (0.00%)
Closing price 05/1/2025 04:00 PM Eastern
Extended Trading
$1.30 +0.03 (+2.28%)
As of 05/1/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fractyl Health EPS Results

Actual EPS
-$8.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Fractyl Health Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fractyl Health Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, April 1, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Fractyl Health's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Fractyl Health Earnings Headlines

The next market Nvidia is positioned to dominate …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.
See More Fractyl Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fractyl Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fractyl Health and other key companies, straight to your email.

About Fractyl Health

Fractyl Health (NASDAQ:GUTS), a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

View Fractyl Health Profile

More Earnings Resources from MarketBeat